Cara Therapeutics (CARA)

Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company developing novel products to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate is intravenous CR845, which has completed phase 2 clinical trials for the treatment acute postoperative pain and is in phase 2 for the treatment of uremic pruritus (itching in dialysis patients). The company is also developing an oral version of CR845 that has completed phase 1 clinical trial for the treatment of moderate-to-severe acute and chronic pain.

Published Reports

CARA 3Q18 rev
CARA-2Q18-rev.pdf
CARA VFMCRP ex-US licensing rev
CARA 1Q18 rev
CARA 4Q17 rev
CARA Oral CR845 in Pruritus
CARA oral cr845 for OA 6.29.17
CARA BTD rev
CARA IV CR845 int
CARA KOL bfast rev
CARA 1Q17 rev
CARA phase 1 safety rev
CARA pruritus data 3 28 17 rev
CARA 4Q16 rev
CARA KOL call 12.12.16_JFM rev
CARA-3Q16.JFM-edits-rev
CARA 2Q16 rev
CARA 1Q16 rev
CARA Clinical hold lift 4.20.16 rev
CARA 4Q15 3.11.16 revb
CARA clinical hold.2.29.16 rev
CERC CEO change 12 21 15 (1) rev
CARA p2a oral 12 9 15
CARA 3Q15_JFM2 rev
CARA 2Q15 rev
CARA pruritus 7.23.15 rev
CARA.KOL call.6.4.15 rev
CARA 1Q15.5.13.15 JFM final edit
CARA intiation